Results 61 to 70 of about 489 (130)

Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report

Monaldi Archives for Chest Disease
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes, João Gomes Carvalho, Patrícia Rodrigues, Manuela França   +3 more
doaj   +1 more source

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. [PDF]

Nat Cardiovasc Res
AbstractHypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly ...
Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI.   +19 more
europepmc   +4 more sources

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions

Monaldi Archives for Chest Disease
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo   +7 more
doaj   +1 more source

A scoping review identified additional considerations for defining estimands in cluster randomised trials [PDF]

OBJECTIVE: An estimand is a clear description of the treatment effect a study aims to quantify. The ICH E9(R1) addendum lists five attributes that should be described when defining an estimand.
Bi, Dongquan, Copas, Andrew, Kahan, Brennan C, Li, Fan   +3 more
core  

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy [PDF]

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable ...
Biagini, Elena, Charron, Philippe, Desai, Milind Y., Elliott, Perry, Fernandes, Fabio, Gonzalez-Lopez, Esther, Haelst, Paul L. van, Haugaa, Kristina Hermann, Kramer, Christopher M., Maurizi, Niccolo, Meder, Benjamin, Michels, Michelle, Owens, Anjali, Yuasa, Shinsuke   +13 more
core   +2 more sources

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies

The Egyptian Heart Journal
Background Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations.
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Muinat Moronke Adeyanju, Victoria Biola Edema   +5 more
doaj   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy [PDF]

Background: Cardiopulmonary exercise testing (CPET) is essential for assessing patients with hypertrophic cardiomyopathy (HCM), but the role of pulmonary function testing (PFT) in refining patient stratification remains underexplored.
Agostoni, Piergiuseppe, Baracchini, Nikita, Cadeddu, Christian, Campana, Nicola, Campodonico, Jeness, Capovilla, Teresa Maria, Capra, Nicolò, Cosimo, Carriere, Galotta, Arianna, Magrì, Damiano, Mapelli, Massimo, Mattavelli, Irene, Merlo, Marco, Nava, Alessandro, Pezzuto, Beatrice, Rossi, Maddalena, Rubbo, Filippo Maria, Salvioni, Elisabetta, Sinagra, Gianfranco, Tavčar, Irena, Vignati, Carlo, Willixhofer, Robin   +21 more
core   +1 more source

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond [PDF]

, 2022
Olivotto, Iacopo
core   +1 more source